| Dexlansoprazole | Takeda | ||
| 30 mg; Capsule, Delayed Release |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
More Than 5
|
None | ||
|
Less Than 5
|
Less Than 5
|
||
| indicated for healing of all grades of erosive esophagitis (EE) for up to eight weeks. | |||
|
Yes
| |||
| Dexilant | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ** *****'* | ****** *****(**** ** **) | ****** *****(**** ** **) | ****** *****(**** ** **) | ******* | ****** ******* (*** ** **) | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ****** *****(**** ** **) |
| ***** | ****** *****(**** ** **) | ****** *****(**** ** **) | ****** *****(**** ** **) | ******* | ****** ******* (*** ** **) | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ****** *****(**** ** **) |
| ******(***) | ****** *****(**** ** **) | ****** *****(**** ** **) | ****** *****(**** ** **) | ******* | ****** ******* (*** ** **) | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ****** *****(**** ** **) |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ** *****'* | *** \ ** | *** *, **** | ******* | **** | ****** **** ******** |
| ***** | *** \ ** | *** *, **** | ******* | **** | ****** **** ******** |
| ******(***) | *** \ ** | *** *, **** | ******* | ******** | ******** ** *** **, **** |
| Dexlansoprazole | Takeda | ||
| 60mg; Capsule, Delayed release |
Less Than $1000 mn
|
||
|
Less Than 5
|
More Than 5
|
||
|
More Than 5
|
None | ||
|
Less Than 5
|
Less Than 5
|
||
| indicated for healing of all grades of erosive esophagitis (EE) for upto eight weeks | |||
|
Yes
| |||
| Dexilant | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ** *****'* | ****** *****(**** ** **) | ****** *****(**** ** **) | ****** *****(**** ** **) | ******* | ****** ******* (*** ** **) | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ****** *****(**** ** **) |
| ***** | ****** *****(**** ** **) | ****** *****(**** ** **) | ****** *****(**** ** **) | ******* | ****** ******* (*** ** **) | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ****** *****(**** ** **) |
| ******(***) | ****** *****(**** ** **) | ****** *****(**** ** **) | ****** *****(**** ** **) | ******* | ****** ******* (*** ** **) | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ****** *****(**** ** **) |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ** *****'* | ** \ ** | *** *,**** | ******* | **** | ****** **** ******** |
| ***** | ** \ ** | *** *,**** | ******* | **** | ****** **** ******** |
| ******(***) | *** \ *** | *** **,**** | ******* | ******** | ******** ** *** **, **** |
Download ParaIV Report